XERS - Xeris Pharmaceuticals: Strong Growth In COVID-19 Headwinds Leads To Unjustified Sell-Off
- Xeris Pharmaceuticals recently reported their Q1 earnings with a slight beat on EPS and revenue. Unfortunately, Xeris reported in the middle of the healthcare sell-off and XERS was unjustly punished.
- The company's flagship product, Gvoke, continues to report impressive commercial numbers despite significant COVID-19 headwinds. Gvoke's recent success has encouraged the company to expand their commercial team.
- Back in February, Xeris received EU and UK approval for Gvoke (Ogluo) and is now looking for a European commercial partner.
- The recent sell-off has knocked the premium out of the share price. I believe XERS is undervalued considering its growth potential and potential upcoming catalysts.
For further details see:
Xeris Pharmaceuticals: Strong Growth In COVID-19 Headwinds Leads To Unjustified Sell-Off